中国肺癌杂志2025，Vol.28Issue(8)：638-643,6.DOI:10.3779/j.issn.1009-3419.2025.106.25
达拉非尼联合曲美替尼治疗BRAF p.L485_T488delinsF突变转移性非小细胞肺癌1例
A Case of Metastatic Non-small Cell Lung Cancer with Rare BRAF p.L485_T488delinsF Mutation Treated with Dabrafenib and Trametinib
王云菲 1赵文 1杨闯 1张荣雨 1王程君 1韩春燕 2李际盛1
作者信息
- 1. 250012 济南,山东大学齐鲁医院肿瘤内科
- 2. 250011 济南,山东中医药大学附属医院肿瘤放疗科
- 折叠
摘要
Abstract
The v-Raf murine sarcoma viral oncogene homolog B(BRAF)gene is one of the most critical proto-oncogenes and functions as a key regulator in the mitogen-activated protein kinase(MAPK)/extracellular signal-regulated kinase(ERK)signaling pathway.The incidence of BRAF mutations in non-small cell lung cancer(NSCLC)patients ranges from 1.5％to 5.5％,with BRAF V600 mutations accounting for approximately 30％-50％of all BRAF mutations,among which BRAF V600E represents the most prevalent mutation type.Currently,the combination of Dabrafenib and Trametinib has been recommended as first-line therapy for BRAF V600-mutant NSCLC by multiple domestic and international guidelines including National Comprehensive Cancer Network(NCCN),European Society of Medical Oncology(ESMO),and Chinese Society of Clinical Oncology(CSCO).However,there are no clear targeted treatment recommendations for BRAF non-V600 mutations.Although case reports suggest that Dabrafenib combined with Trametinib may be effective for patients with BRAF non-V600 mutations,the efficacy and safety require further validation due to limited sample size and lack of large-scale clinical trial data.This article reports a case of NSCLC with a rare BRAF insertion and deletion mutation that responded well to the treatment of Dabrafenib in combination with Trametinib,aiming to enhance clinicians' understanding of such NSCLC cases with extremely rare mutation and provide a reference for future treatment strategies.关键词
肺肿瘤/BRAF突变/达拉非尼/曲美替尼/靶向治疗Key words
Lung neoplasms/BRAF mutation/Dabrafenib/Trametinib/Targeted therapy引用本文复制引用
王云菲,赵文,杨闯,张荣雨,王程君,韩春燕,李际盛..达拉非尼联合曲美替尼治疗BRAF p.L485_T488delinsF突变转移性非小细胞肺癌1例[J].中国肺癌杂志,2025,28(8):638-643,6.
